Elanco Animal Health (ELAN)
NYSE: ELAN · Veterinary Pharmaceuticals · Indianapolis, IN
Our rating: Neutral
Neutral reaffirmed at $26.84, moderate conviction, November 9, 2026.
Breaks if: The Neutral view tips Cautious if free cash flow falls below $200M on a trailing twelve-month basis across two consecutive quarterly reports, or if revenue growth decelerates to below 2% year-over-year — either would signal the recovery narrative is stalling in a way the current valuation does not reflect. It tips Positive if free cash flow reaches $400M or above on a trailing twelve-month basis while revenue growth holds above 7% for two consecutive quarters, indicating that amortization drag is being offset by genuine operating leverage and the FCF yield is re-rating toward something that supports the current price.
Key figures
| Market value | $12.9B |
|---|---|
| Revenue, last 12 months | $5.1B |
| Net income, last 12 months | −$147M |
| Free cash flow, last 12 months | $408M |
| Price to earnings | n/a |
| Free cash flow yield | 3.2% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −2.2% |
| Beta to the S&P 500 | 1.22 |
| Volatility, annualized | 47.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.3B | 11.3% | $0.04 | $156M |
| June 30, 2026 | $1.4B | 10.2% | $0.11 | $244M |
| March 31, 2026 | $1.4B | 14.9% | $0.11 | −$38M |
| December 31, 2025 | $1.1B | 12.2% | $-0.56 | $46M |
| September 30, 2025 | $1.1B | 10.4% | $-0.07 | $127M |
| June 30, 2025 | $1.2B | 4.8% | $0.02 | $180M |
| March 31, 2025 | $1.2B | −1.0% | $0.13 | −$69M |
| December 31, 2024 | $1.0B | −1.4% | $-0.02 | $130M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.28B: Claude 72%, Gemini 90%, Mistral 60%
- Diluted earnings per share are above zero: Claude 60%, Gemini 80%, Mistral 85%
- Free cash flow for the quarter is at least $0.05B: Claude 65%, Gemini 90%, Mistral 80%
13 ledger entries and 51 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.